- $16.19m
- -$40.86m
- $0.19m
U.S. STOCKS ON THE MOVE-Charles River, Oracle, TD Synnex
US STOCKS ON THE MOVE-Charles River, Oracle, TD Synnex
U.S. STOCKS ON THE MOVE-CoreWeave, Versant Media, BlackBerry
aTyr rises as FDA aligns on late-stage lung disease study plan
Brief: aTyr Pharma Announces Alignment With FDA On Phase 3 Study Of Efzofitimod In Pulmonary Sarcoidosis
Brief: Atyr Pharma Provides Update On Timing Of Regulatory Response For Planned Phase 3 Study Of Efzofitimod In Pulmonary Sarcoidosis
aTyr Pharma Inc reports results for the quarter ended June 30 - Earnings Summary
aTyr Pharma Q2 net loss narrows
Advisory: Alerts on Ethos Technologies' Q2 results wrongly attributed to Atyr Pharma withdrawn
Ethos Technologies Q2 revenue rises 113% on policy growth
aTyr Pharma Inc expected to post a loss of 12 cents a share - Earnings Preview
Brief: aTyr Pharma - Co And Kyorin Terminate Collaboration Agreement Effective July 30, 2026 - SEC Filing
Brief: aTyr Pharma Q1 Net Income USD -166.391 Million
Brief: Atyr Pharma Announces Scheduling Of FDA Type C Meeting To Discuss Efzofitimod Program In Pulmonary Sarcoidosis
U.S. RESEARCH ROUNDUP- aTyr pharma, Clear Secure, Neumora Therapeutics
U.S. STOCKS ON THE MOVE- Western Alliance Bancorp, CoreWeave, Alphabet
aTyr plunges as lung disease drug misses main goal in late-stage study
U.S. STOCKS ON THE MOVE-Union Pacific, Corteva, Novocure
aTyr plunges as lung disease drug misses main goal in late-stage study